印度发现90%的咳嗽糖浆工厂在与受污染产品有关的儿童死亡后存在重大安全缺陷。 India finds major safety flaws in 90% of cough syrup factories after child deaths linked to contaminated products.

印度的药物监管者检查了90%的咳嗽糖浆制造商 — — 约1 100个设施 — — 并发现广泛的合规问题,包括制造业做法不良、原材料测试不足以及生产方法有缺陷。 India’s drug regulator inspected 90% of its cough syrup manufacturers—about 1,100 facilities—and found widespread compliance issues, including poor manufacturing practices, inadequate raw material testing, and flawed production methods. 调查结果显示,自2022年以来,印度和国外受污染的糖浆造成多名儿童死亡。 The findings follow multiple child deaths linked to contaminated syrups in India and abroad since 2022. 该机构还积极检查了另外1 250个毒品单位,但没有披露违规率或停业情况。 The agency has also proactively inspected 1,250 additional drug units but did not disclose violation rates or shutdowns. 加强监督的努力包括雇用1 500名新工作人员,试行AI,以便更快批准,以及通过取消无异议证书要求来简化向主要市场的出口。 Efforts to strengthen oversight include hiring 1,500 new staff, piloting AI for faster approvals, and streamlining exports to major markets by removing no-objection certificate requirements.